Study on TIL for the Treatment of Advanced Solid Tumors

  • STATUS
    Recruiting
  • End date
    Apr 22, 2024
  • participants needed
    20
  • sponsor
    Shanghai Juncell Therapeutics
Send
Updated on 4 October 2022
See if I qualify

Summary

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with Advanced malignant solid tumors.Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with fludarabine and cyclophosphamide.

Details
Condition Advanced Solid Tumors
Treatment Tumor Infiltrating Lymphocytes (TIL)
Clinical Study IdentifierNCT04967833
SponsorShanghai Juncell Therapeutics
Last Modified on4 October 2022

Eligibility

 Yes No Not Sure

Inclusion Criteria

Age: 18 years to 75 years
Histologically diagnosed as primary/relapsed/metastasized malignant tumors
Expected life-span more than 3 months
Karnofsky≥60% or ECOG score 0-2
Test subjects have failed standard treatment regimens, or there are no standard treatment regimens available
Test subjects must have tumor regions eligible for biopsy or resection, or malignant body fluid where TILs can be isolated
At least 1 evaluable tumor lesion
Hematology and Chemistry（within 7 days prior to enrollment）
Absolute count of white blood cells≥2.5×10^9/L
Absolute count of neutropils≥1.5×10^9/L
Absolute count of lymphocytes ≥0.7×109/L；
Platelet count≥100×10^9；
Any malignant tumor-targeting therapies, including radiotherapy, chemotherapy and biologics must cease 28 days before obtaining TILs
hemoglobin≥90 g/L
Activated partial thromboplastin time (APTT) ≤1.5xULN (Unless received anticoagulant therapy within the previous 3 days)
Be able to understand and sign the informed consent document
International normalized ratio (INR) ≤1.5xULN (Unless received anticoagulant therapy within the previous 3 days)
Be able to stick to follow-up visit plan and other requirements in the agreement
Serum creatinine ≤1.5mg/dL(or ≤132.6μmol/L), or clearance rate≥50mL/min
Serum ALT/AST ≤3×ULN(subjects with liver metastasis ≤3×ULN)
Totol bilirubin≤1.5×ULN
No absolute or relative contraindications to operation or biopsy
Test subjects with child-bearing potential must be willing to practice approved highly effective methods of contraception at the time of informed consent, and continue within 1 year after the completion of lymphodepletion；

Exclusion Criteria

Forced expiratory volume in one second (FEV1) less than 2L, diffusing capacity of the lung for carbon monoxide (DLCO) (calibrated) less than 40%
Significant cardiovascular anomalies according to any of the following definition: New York Heart Association (NYHA) Grade III or IV congestive heart failure, clinically significant low blood pressure, uncontrollable symptomatic coronary artery diseases, or ejection fraction less than 35%; Severe cardiac rhythm and conduction anomaly, such as ventricular arrhythmia requiring clinical intervention, second-third degree atrio-ventricular conductive block, etc
Human immunodeficiency virus (HIV) infection or anti-HIV antibody positive, active HBV or HCV infection (HBsAg positive and/or anti-HCV positive), syphilis infection or Treponema pallidum antibody positive
Severe physical or mental diseases
Need glucocorticoid treatment, and daily dose of Prednisone greater than 15mg (or equivalent doses of hormones) or outoimmune diseases requiring immunomodulatory treatment
Having been treated within a month or being treated now with other medicines, or other biologic therapy, chemo-or radiotherapy
History of allergy to chemical compound consisting of chemical and biologic substances resembling cell therapy
Having received immunotherapy and developed irAE level greater than Level 3
Previous anti-tumor treatment AE did not return to CTCAE5.0 version grade 1 or below (toxicity considered by the investigator as non-safety concerns like alopecia excluded)
Females in pregnancy or lactation
Have a systemic active infection requiring treatment, or have positive blood cultures(or imaging evidence of infection)
Researchers considering the test subject as having a history of other severe systemic diseases, or other reasons inappropriate for the clinical study
History of organ transplantation, allogeneic stem cell transplantation, and renal replacement therapy
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note